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Abstract
Background: Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral
administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal
adjuvants, and no such adjuvant has yet been approved for human use.
Methodology/Principal Findings: We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show
here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for
protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of
filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of
endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative
induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced
mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed
after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked
to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect.
Conclusions/Significance: Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal
influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and
adjuvant-free nasal vaccination against influenza.
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Introduction
Respiratory pathogens are the leading cause of global deaths
from infectious diseases [1]. Vaccines against some respiratory
pathogens are available, and most often these vaccines are
administered by needle injection. However, intranasal (i.n.), and
more generally mucosal vaccination can be an effective way to
immunize against respiratory infections. This mode of vaccine
delivery has a number of advantages over conventional
vaccination [2], including needle-free administrations of vaccines
and the potential of inducing immunity at mucosal sites, the
entry port of respiratory pathogens. However, most antigens are
poorly immunogenic when applied by the nasal route, and
potent adjuvants are often needed. Examples of such adjuvants
include genetically detoxified cholera toxin and the related
Escherichia coli heat-labile enterotoxin, which are among the most
potent mucosal adjuvants known. However, their i.n. application
in the formulation of an influenza vaccine has raised safety
concerns as it resulted in unacceptable adverse events, such as
Bell’s palsy [3]. As an alternative way to effectively deliver
antigens to the respiratory mucosa, live attenuated vectors have
also been explored. Live attenuated influenza virus has been
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successfully tested in humans, including infants, and was found
to be safe and able to induce protective immunity after a single
i.n. application [4].
We have recently developed a live attenuated Bordetella pertussis
vaccine candidate, initially designed to protect against whooping
cough. This vaccine candidate, named BPZE1, was generated by
the genetic removal or inactivation of three major B. pertussis toxins
[5]. In preclinical models, it showed an excellent safety profile,
including in severely immuno-compromized animals [6]. Despite
its strong attenuation, BPZE1 is able to colonize the respiratory
tract and to induce strong and long-lasting protective immunity,
even in 1-week-old mice [7]. These properties and the document-
ed genetic stability of the strain [8] have allowed BPZE1 to be
downgraded from biosafety level 2 to level 1 and to undergo first-
in-man clinical trials (ClinicalTrials.gov NCT01188512).
Furthermore, BPZE1 displays potent anti-inflammatory prop-
erties and was found to protect against experimental allergic
asthma [9,10] and against mortality induced by highly pathogenic
influenza viruses [11] by dampening the virus-induced cytokine
storm.
We have previously shown that recombinant B. pertussis strains
can also be used as multivalent vaccine candidates able to protect
simultaneously against both pertussis and heterologous pathogens
[12–17]. Here, we used a truncated form of filamentous
hemagglutinin (FHA), named Fha44, containing its secretion
determinant to export the 23-amino-acid extracellular domain of
the influenza A virus matrix protein M2 (M2e) from BPZE1. M2e
is remarkably well conserved among human influenza A virus
isolates and has been proposed as a universal influenza vaccine
antigen [18–21]. Fused to the hepatitis B virus core protein as a
virus-like particle (VLP) M2e conferred protection against a lethal
influenza A virus challenge in the mouse model [19].
In a previous study, BPZE1 has been engineered to produce
one, two or three copies of M2e fused to full-length FHA [17].
However, secretion efficiency decreased with the numbers of M2e
copies, and the hybrid protein containing 3 copies of M2e was
barely detectable in the culture supernatant of the recombinant
strain. Antibody responses to M2e in mice were detectable, but
weak, even after three i.n. administrations of high doses of the
recombinant strain. Since Fha44 is more efficiently secreted than
full-length FHA [22], we used this protein as a carrier for M2e in
order to optimize secretion efficiency and immunogenicity. We
show here that the BPZE1 derivative producing Fha44-M2e is
able to induce an immune response only in the absence of full-
length FHA. Furthermore, i.n. administration of FHA-deficient
BPZE1 producing Fha44-M2e effectively primed the immune
system for a heterologous boost with an i.n. administered M2e-
VLP vaccine. This mucosal prime-boost regimen, in the absence
of adjuvants, protected mice against a lethal challenge with




To express the extracellular domain of the M2 protein (M2e) of
influenza A virus in BPZE1, we used Fha44 as carrier. Fha44 is the
80-kDa N-terminal fragment of FHA and is better secreted by B.
pertussis than full-length FHA [22]. Three copies of the M2e-
coding sequence were fused to the Fha44-coding sequence. The
M2e sequence differs from the original sequence by the
substitution of the two cysteines (Cys-16 and Cys-18) for serines
in order to optimize secretion by Fha44, as we have previously
shown that the formation of disulfide bonds may hamper Fha4-
mediated secretion [23]. The construct was inserted into the
BPZE1 chromosome at the dnt locus by allelic exchange, placing
the transgene under the control of the dnt promoter. This yielded
the recombinant strain BPZM2e.
Crude culture supernatants and whole cell extracts of BPZE1
and BPZM2e were examined by immunoblot analysis using an
anti-M2e monoclonal antibody. As shown in Figure 1, a 94-kDa
band, corresponding to the expected size of the Fha44-3M2e
chimeric protein, was detected in the culture supernatant of the
recombinant strain. A protein of similar size reactive with the
anti-M2e antibody was also detected in the whole cell extracts.
This observation indicates that the chimeric protein was
secreted from the recombinant strain and was also associated
with BPZM2e cells.
Lung Colonization and Immunogenicity of BPZM2e
To evaluate the general fitness of BPZM2e its in vitro growth
kinetics was compared to that of the parent strain BPZE1. As
shown in Figure 2A, there was no significant difference between
the two strains, indicating that the general bacterial fitness was not
impaired by the production of Fha44-3M2e.
To study the ability of BPZM2e to colonize the murine
respiratory tract, BALB/c mice were inoculated i.n. with 106 CFU
of BPZM2e or with non-recombinant BPZE1, and their coloni-
zation profiles were compared. The colonization profile of
BPZM2e was indistinguishable from that of the corresponding
parental strain BPZE1 (Figure 2B), indicating that the production
of Fha44-3M2e does not alter the ability of the bacteria to colonize
the lungs of mice.
The antibody responses to the M2e peptide were examined by
ELISA at different time points after administration of 106 CFU of
Figure 1. Immunoblot analysis of BPZM2e. Culture supernatants
(panel A) and whole cell lysates (panel B) of BPZE1 and BPZM2e were
subjected to SDS-PAGE and immunoblot analysis using a monoclonal
antibody to M2e. The molecular weight markers and their sizes in kDa
are indicated on the left.
doi:10.1371/journal.pone.0059198.g001
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BPZM2e to the mice. However, no M2e-specific antibodies were
detected in the serum at any time point (data not shown). The
BPZM2e dose was then increased ten-fold, and BALB/c mice
were i.n. immunized twice with a 4-week interval with 107 CFU of
BPZE1 or recombinant BPZM2e. Sera were collected at 2 and 4
weeks after the first immunization, and 2 weeks after the last
immunization to measure the systemic anti-M2e IgG response.
Again, no significant antibody response to M2e was detected in the
sera (Figure 2C).
Inactivation of FHA and Characterization of BPZM2e-
DFHA
We hypothesized that the endogenous FHA in BPZM2e may
perhaps act as an immunodominant antigen over Fha44-3M2e.
Therefore, we inactivated the gene coding for full-length FHA
(fhaB) in BPZM2e by introducing a pFus2 derivative that
contains an internal fragment of fhaB [24]. As pFus2 cannot
replicate in B. pertussis, the integration of the plasmid into the
fhaB gene is forced by homologous recombination, thereby
interrupting this gene. However, an approximately 20-kDa N-
terminal fragment may still be produced. The integrants were
selected on BG blood agar containing 100 mg/ml streptomycin
and 10 mg/ml gentamycin, and the resulting strain was named
BPZM2e-DFHA.
The absence of full length FHA in BPZM2e-DFHA was verified
by SDS-PAGE and staining with Coomassie blue, and the
presence of Fha44-3M2e in the culture supernatant was
determined by immunoblot analysis. SDS-PAGE and Coomassie
blue staining showed the absence of the 220-kDa protein,
corresponding to FHA, in the culture supernatant of the
BPZM2e-DFHA mutant strain, as well as in that of BPGR4, a
known FHA-deficient strain, used as a control (Figure 3A).
Immunoblot analyses of crude culture supernatants indicated that
the FHA-deficient mutant produced at least as much Fha44-3M2e
as the BPZM2e parent strain (Figure 3B). As expected, no
immunoreactive band was detected in the culture supernatant of
BPZE1.
Lung Colonization and Immunogenicity of BPZM2e-
DFHA
Many studies have indicated a crucial role of FHA in the
colonization of the respiratory tract [25–28]. The ability of FHA-
deficient mutants to colonize the murine respiratory tract is
particularly impaired when pertussis toxin (PTX) is also absent or
genetically inactivated [28], which is the case for all BPZE1
derivatives [5]. However, due to the presence of Fha44-3M2e,
and/or an approximately 20-kDa N-terminal fragment of FHA
that still might be produced instead of full-length FHA, it may be
possible that BPZM2e-DFHA can still colonize sufficiently well to
induce immune responses [27].
To investigate the colonization profile of the recombinant strain
with genetically inactivated FHA, BALB/c mice were infected i.n.
with 107 CFU of BPZM2e-DFHA, and the bacterial load in the
lungs was followed for up to 28 days. Both BPZE1 and BPZM2e-
DFHA colonized the lungs and persisted in the lungs of the mice at
similar levels, although at day 3 after inoculation slightly less
BPZM2e-DFHA than BPZE1 was detected in the lungs of the
mice (Figure 4A).
The immunogenicity of BPZM2e-DFHA was next evaluated
after two i.n. administrations with a 4-week interval. The sera were
collected 2 weeks after the last immunization, and the systemic
anti-M2e antibody response was determined by peptide ELISA.
BPZM2e-DFHA induced high levels of systemic IgG against M2e,
whereas two administrations of BPZM2e, producing FHA, or
BPZE1 did not result in a significant anti-M2e IgG response
(Figure 4B). These observations indicate that the absence of FHA
strongly increases the immune responses to M2e after i.n.
Figure 2. Growth curves, colonization capacity and immuno-
genicity of BPZM2e. (A) The growth curves of BPZE1 (closed circles)
and BPZM2e (closed squares) in Stainer Scholte medium were
determined by OD measurements at 600 nm over the indicated
periods of time. (B) BALB/c mice were inoculated i.n. with 106 CFU of
BPZE1 or recombinant BPZM2e. Bacterial colonization of the lungs by
BPZE1 (closed circles) and BPZM2e (closed squares) was measured in
CFU over the indicated periods of time following i.n. administration. (C)
BALB/c mice were i.n. immunized twice at a 4-week interval with
107 CFU of BPZE1 or recombinant BPZM2e as indicated. Sera were
collected at indicated time points after the first immunization, and
serum IgG responses to M2e were determined by an M2e-peptide
ELISA.
doi:10.1371/journal.pone.0059198.g002
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immunization with recombinant BPZM2e-DFHA without affect-
ing its lung colonization capacity.
Heterologous i.n. Prime/boost Vaccination and
Protection against Influenza Challenge
To investigate the priming effect of BPZM2e-DFHA, BALB/c
mice were primed i.n. with 107 CFU BPZM2e-DFHA or BPZE1
and boosted i.n. with M2e-VLP [20] in the absence of adjuvant.
Systemic M2e-specific IgG responses were determined by ELISA
two weeks after the last immunization. Mice primed with
BPZM2e-DFHA and boosted with M2e-VLP mounted a signifi-
cantly higher antibody titer than mice that had been primed with
BPZE1 and subsequently received M2e-VLP. No anti-M2e
antibodies were detectable in the control group of mice that had
received twice PBS (Figure 5A). Priming with BPZM2e-DFHA did
not modify the antibody isotype profile to M2e, compared to
priming with BPZE1, as the IgG/IgG2a ratios were similar in both
groups (Figure 5B).
Two weeks after the last immunization, the mice were
challenged with a dose that corresponds to 4 LD50 of the
mouse-adapted H3N2 influenza A virus X47. The M2e sequence
of the X47 strain differs from that of the sequence used in
BPZM2eDFHA by one amino acid, Ser-12 to Asn, in addition to
the two cysteine to serine changes. Three mice per group were
used to determine the viral titers in the lung homogenates at day 4
after challenge. The mice primed with BPZM2e-DFHA and
boosted with M2e-VLP had significantly lower viral loads in the
lungs than BPZE1-primed mice boosted with M2e-VLP and than
sham-vaccinated mice (Figure 5C). These results indicate that i.n.
administration of BPZM2e-DFHA can efficiently prime for
protective anti-viral immunity. When the mice were vaccinated
once or twice with BPZM2e-DFHA without a M2e-VLP boost, no
reduction in viral load was observed (data not shown), indicating
that the M2e-VLP boost is necessary to reduce lung virus
replication.
To investigate the effect of the heterologous prime-boost
vaccination on mouse survival after viral challenge, we followed
the mortality of BPZM2e-DFHA-primed and M2e-VLP-boosted
mice for up to two weeks. The percent of survival was significantly
higher in the group that had received BPZM2e-DFHA and M2e-
VLP compared to the negative control group and the group that
had received BPZE1 followed by M2e-VLP (Figure 5D). Again,
BPZM2e-DFHA alone given once or twice did not result in a
Figure 3. SDS-PAGE and Immunoblot analyses of culture supernatants from BPZM2e and BPZM2e-DFHA. Unconcentrated culture
supernatants of the indicated strains were subjected to SDS-PAGE and Coomassie-blue staining (A) and Immunoblot analysis (B) using a monoclonal
antibody to M2e. The molecular weight markers and their sizes in kDa are indicated on the left.
doi:10.1371/journal.pone.0059198.g003
Figure 4. Colonization capacity and immunogenicity of BPZM2e-DFHA. (A) BALB/c mice were i.n. infected with 107 CFU of BPZE1 (black
dots) or BPZM2e-DFHA (black squares), and the CFU in the lungs were quantified at the indicated time points. (B) BALB/c mice were i.n. immunized
twice at a 4-week interval with 107 CFU of the indicated strains. Sera were collected two weeks after the last immunization, and serum IgG responses
to M2e were determined by an M2e-peptide ELISA. The results are expressed as means 6 standard errors. ***, p,0.001.
doi:10.1371/journal.pone.0059198.g004
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significant effect on survival (data not shown), indicating that, as
for the effect on the viral load, the M2e-VLP boost was important
to protect against mortality.
Protection against B. pertussis Challenge
Since our general objective is to construct BPZE1 derivatives
that are able to protect against both pertussis and other
respiratory infections, it was important to verify that the genetic
alterations in BPZM2e-DFHA did not alter its protective
properties against pertussis. To evaluate the protective effect
of BPZM2e-DFHA against B. pertussis, BALB/c mice were
immunized i.n. with 105 CFU BPZE1 [29] or BPZM2e-DFHA
and challenged 4 weeks later with 106 CFU of virulent B.
pertussis BPSM. Seven days after challenge, the bacterial load
was quantified in the lungs. As shown in Figure 6, a single
administration of BPZM2e-DFHA or BPZE1 provided similar
levels of protection against BPSM challenge. These data
indicate that the inactivation of full-length FHA and the
production of Fha44-3M2e do not interfere with the protective
potential of BPZE1 against challenge with virulent B. pertussis.
Discussion
Influenza remains a major public health problem world-wide
and causes serious illness in 3 to 5 million people, including
200,000 to 500,000 deaths at each flu season. It is the seventh
leading cause of death in the United States [30]. Particularly the
elderly, immunocompromized and the very young are at risk for
severe influenza and account for more than 90% of all influenza-
Figure 5. Anti-M2e IgG responses and protection against viral challenge after heterologous prime/boost vaccination. BALB/c mice
were i.n. immunized with 107 CFU of BPZE1 or BPZM2e-DFHA as indicated and boosted i.n. 4 weeks later with 10 mg M2e-VLP. Negative control mice
received PBS. Sera were collected 2 weeks after the last immunization, and serum IgG responses to M2e were determined by an M2e-peptide ELISA
(A). IgG1 and IgG2a ratios (B) were determined for the groups primed with BPZE1 or BPZM2e-DFHA and boosted with M2e-VLP. (C) Groups of 3 BALB/
c mice were i.n. primed with 107 CFU of BPZE1 or BPZM2e-DFHA and boosted 4 weeks later with 10 mg M2e-VLP. Two weeks after the last
immunization the mice were challenged with 4 LD50 of influenza A virus, and the viral loads in the lungs were measured at 4 days post challenge by
TCID50 quantification. The results are expressed as means of log106 standard errors. (D) Groups of 9 BALB/c mice were i.n. primed with 10
7 CFU of
BPZE1 or BPZM2e-DFHA and boosted 4 weeks later with 10 mg M2e-VLP. Two weeks after the last immunization the mice were challenged with 4
LD50 of influenza A virus, and the percent of survival after challenge was monitored for up to 2 weeks. *, p,0.05; ns, not significant.
doi:10.1371/journal.pone.0059198.g005
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related deaths. In addition to seasonal influenza, pandemic
influenza constitutes a constant public health threat, and due to
the modern lifestyle of human society, there is an elevated risk for
the emergence of new virus reassortants with increased virulence.
Antiviral drugs may be an effective way of treating the disease.
However, their effectiveness is limited by the need for early
initiation of treatment in the course of infection [31] and by the
risk of resistance to the drugs [32]. Vaccination is the most cost-
effective measure to control the disease.
Current influenza vaccines are based on three virus strains, used
either as inactivated or live attenuated whole viruses, as split virus
vaccines or as subunit vaccines and comprise essentially the
immunodominant antigens hemagglutinin and neuraminidase.
However, the antigenic make-up of the virus constantly changes
through two mechanisms called ‘‘antigenic drift’’ and ‘‘antigenic
shift’’ [33]. As a consequence, the vaccines have poor clinical
efficacy against viral strains that do not match the vaccine strain
[34], and vaccine types have to be adapted nearly every year to the
viral types that are predicted to circulate during the forthcoming
winter season.
The search for a universal influenza vaccine has thus been an
endeavour for decades now. M2e is the extracellular domain of the
influenza virus matrix protein M2, and its amino acid sequence is
remarkably conserved among viral strains [18]. Although present
in only small amounts on the viral particles, it is abundantly
expressed on the surface of infected cells, and antibodies to this
peptide have been reported to limit viral replication and to protect
from challenge with various viral strains. It has therefore been
proposed as a universal influenza vaccine candidate [19].
In this study, we used recombinant derivatives of the novel live
attenuated B. pertussis vaccine candidate BPZE1 to present M2e to
the respiratory mucosa in order to induce anti-M2e antibodies by
i.n. administration. In addition to logistic advantages, this needle-
free approach is also expected to induce broader cross-protection
against heterologous virus strains, compared to parenteral
vaccination [35]. Although due to its strong sequence conserva-
tion, this may be less an issue when M2e is used as an antigen.
Nevertheless, some sequence variations in M2e have been detected
among strains. BPZE1 has already been used in experimental
animal models to present heterologous antigens [16,17], including
M2e [17]. Previous work has used full-length FHA or the
autotransporter BrkA to surface display the heterologous antigen
on BPZE1. However, the insertion of 3 copies of M2e into full-
length FHA induced only a modest serum antibody response to the
antigen, even after repeated administrations of the recombinant
strain. In addition, the insertion of three copies of M2e into FHA
significantly affected FHA secretion into the extracellular milieu
and the ability of the recombinant strain to colonize the mouse
lungs [17]. Decreasing the numbers of M2e copies in FHA
improved FHA secretion and lung colonization, but at the expense
of M2e immunogenicity.
In this study we used Fha44, a truncated form of FHA as a
genetic fusion partner for M2e. Fha44 is more efficiently secreted
than FHA in B. pertussis [22]. The fusion of 3 copies of M2e to
Fha44 did not appear to impair the secretion of the Fha44-3M2e
chimera, as the recombinant protein could readily be detected in
crude BPZM2e culture supernatants. Also, the general fitness of
the BPZE1-derivative, and its ability to colonize the mouse
respiratory tract were not affected by the fusion of 3 copies of M2e
to Fha44. Nevertheless, even repeated administrations of BPZM2e
did not result in a detectable antibody response to M2e, nor did
they prime for an anti-M2e antibody response (data not shown).
However, when the chromosomal gene of the full-length FHA
was inactivated by a mutational insertion, the resulting BPZM2e-
DFHA strain induced strong antibody titers against M2e after i.n.
administration. The insertional inactivation probably resulted in
the production of a small truncated N-terminal fragment of FHA
rather than in its total absence. Importantly, the inactivation by
plasmid insertion was stable, as verified after repeated in vitro
culturing and after in vivo passaging (data not shown).
A single i.n. administration of BPZM2e-DFHA also primed
anti-M2e responses, which could be strongly boosted by an i.n.
administration of M2e-VLP. This heterologous prime/boost
regimen resulted in significant protection against lethal challenge
with influenza A virus and in decreased viral load after challenge,
even though the M2e sequence of the challenge strain differed by
three amino acids from that in BPZM2e-DFHA. This slight
sequence variation did thus not hamper the protective effect of the
prime-boost regimen used here.
M2e has been tested before as a nasal vaccine and found to
induce protection by that route. However, protection was achieved
after 3 doses of vaccine and preferably in the presence of a potent
mucosal adjuvant [19,20,36]. In the heterologous prime/boost
strategy described here, a single i.n. administration of the M2e-
VLP provided protection when the mice were primed with
BPZM2e-DFHA. As no nasal adjuvant has yet been approved for
human use, and as BPZE1 has now successfully concluded a phase
I safety trial in humans (Thorstensson et al., in preparation), this
strategy may be a promising approach for needle-free delivery of
universal influenza vaccines.
BPZE1 was originally designed as a priming vaccine against
pertussis for a strategy in which the current acellular vaccines
would serve as booster vaccines to improve protection and
lengthen vaccine efficacy. The results shown here support the
concept that recombinant BPZE1 derivatives can be used as
priming vaccines for multiple respiratory infections by using the
FHA secretion machinery to surface expose or secrete heterolo-
gous protective antigenic peptides. Interestingly, Fha44-3M2e was
only immunogenic when delivered i.n. by a BPZE1 derivative that
did not produce full-length FHA. Although the mechanism of this
effect has not been definitively established yet, it may be related to
Figure 6. Protection against B. pertussis challenge. Groups of 5
BALB/c mice were i.n. immunized with 105 CFU of BPZE1 or BPZM2e-
DFHA and challenged 4 weeks later with 106 CFU of BPSM. Seven days
after infection, the mice were sacrificed and bacterial loads in the lungs
were determined and are expressed as CFU/lung. The results are
expressed as means 6 standard errors. ***, p,0.001.
doi:10.1371/journal.pone.0059198.g006
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the immuno-regulatory properties of full-length FHA. FHA has
been described to inhibit IL-12 production and to stimulate IL-10
production by dendritic cells, resulting in the induction of
regulatory T cells [37]. Alternatively, since FHA forms multimeric
bundles [38], the presence of full-length FHA in BPZM2e may
potentially mask the viral epitope on Fha44-3M2e. Finally, we
cannot exclude that the increased anti-M2e responses may be
related to a potentially slightly higher Fha44-3M2e production in
BPZM2e-DFHA compared to BPZM2e.
In the context of inactive PTX, FHA is important to establish
bacterial colonization in the respiratory tract [28], which, in turn,
is essential for the induction of protective immunity against
pertussis [5]. It was therefore important to observe that the
inactivation of the FHA gene in BPZM2e-DFHA does not impair
the colonization, nor the ability of the strain to protect against
virulent B. pertussis challenge. In BPZM2e-DFHA, Fha44 could
thus functionally replace full-length FHA for colonization and
induction of anti-B. pertussis immunity.
Although M2e has been documented by several studies as a
promising universal vaccine candidate against influenza, other
conserved epitopes have also recently been identified. Studies on
the B cell repertoire of subjects infected with the 2009 pandemic
H1N1 influenza virus have uncovered broadly cross-reactive
epitopes in the hemagglutinin, that can neutralize a variety of
influenza A virus subtypes in vitro [39]. In addition to antibodies,
cross-reactive CD4+ and CD8+ T cells may also play an important
role in protection against influenza [40]. Multimeric vaccine
constructions comprising arrays of several protective and cross-
reactive T and B cell epitopes may thus be an interesting option to
pursue [41,42] and to produce in recombinant BPZE1 derivatives.
Materials and Methods
Ethics Statement
All animal experiments were performed following the
guidelines of the Institut Pasteur de Lille animal study board,
which conforms to the Amsterdam Protocol on animal
protection and welfare, and Directive 86/609/EEC on the
Protection of Animals Used for Experimental and Other
Scientific Purposes, updated in the Council of Europe’s
Appendix A (http://conventions.coe.int/Treaty/EN/Treaties/
PDF/123-Arev.pdf). The animal work also complied with the
French law (nu 87–848 dated 19-10-1987) and the European
Communities Amendment of Cruelty to Animals Act 1976. All
manipulations involving animals were carried out by qualified
personnel. The animal house was placed under the direct
control of the Institut Pasteur de Lille director who is the
‘‘designated responsible person’’ under French law. The study
has been approved by Ethical Committee for experiments on
animals of the region Nord-Pas-de-Calais (approval number AF
03/2009).
Influenza A virus challenge experiments of immunized BALB/c
mice were performed at the Department for Molecular Biomedical
Research, VIB, Ghent, Belgium in a biosafety level 2 contained
animal house. Influenza virus challenge protocols were authorized
by the Institutional Ethics Committee on Experimental Animals
(permit number LA1400091). All efforts were made to reduce
suffering of animals.
Bacterial Strains and Growths Conditions
The B. pertussis strains used in this study are listed in Table 1.
They were grown on Bordet-Gengou agar (Difco, Detroit,
Mich.) supplemented with 1% glycerol, 20% defibrinated sheep
blood, and 100 mg/ml streptomycin (Sigma Chemical Co., St
Louis, Mo.) at 37uC for 72 h. Liquid cultures of B. pertussis were
grown as described previously [43] in Stainer-Scholte medium
[44] containing 1 g/liter heptakis (2,6-di-o-methyl) b-cyclodex-
trin (Sigma).
Construction of Plasmids and Recombinant BPZE1 Strains
The Fha44-3M2e-coding DNA was inserted into the dnt locus of
BPZE1 by allelic exchange, using a plasmid derived from
pJQmp200rpsL12 [45] and containing up- and downstream
regions of the dnt gene, as described by Mielcarek et al. [5] for
the deletion of the dnt gene in BPZE1. This plasmid was named
pJQdntUPLO. To construct pXR1-Fha44, the TCTAGA XbaI
site of pJQdntUPLO was first changed to TCCAGA using
QuickChangeIlH XL (Stratagen) according to the manufacturer’s
instructions. This yielded pXR1. A synthetic gene coding for the
59 part of the fhaB gene was purchased from Eurogentec (Lie`ge,
Belgium). This gene, named fha44c, contains 2,583 bp coding for
amino acids 1 to 861 of FhaB, the precursor of FHA (from
nucleotide position 253 to 2,835, GenBank M60351.1), except for
four silent changes (G354C, C864G, G2,331C and A2,556G), a
27-bp multiple cloning site with the sequence 59-CTTAA-
GACGCGTCATATGGGCGGCCGC-39 and two TGA termi-
nation codons. This sequence was provided in a plasmid named
pUC57-Fha44c, which was digested with XhoI and XbaI. The
fragment corresponding to fha44c was inserted into XhoI/XbaI-
digested pXR1, yielding pXR1-Fha44.
The sequence coding for 3 copies of the M2e peptide was
amplified by PCR from the pGA4-3M2e (purchased from Geneart
AG), containing the coding information for three tandem copies of
M2e. Each M2e copy in pGA4-3M2e is separated by
SGSGGSGGS and cysteine codons at positions 17 and 19 in
M2e were replaced by serine. Oligonucleotides 59-
ACGCGTGTGGAAACTCCTATCCG-39 and 59-CAT-
ATGGCCGCCAGAGCCGCTATCAGAGCTATCGTT-39
were used as primers. The amplified DNA was then inserted into
pCRII-TOPO (Invitrogen). A 273-bp fragment obtained after
MluI/NdeI digestion was inserted into MluI/NdeI-digested pXR1-
Fha44 to yield pHKG3, which was then introduced into E. coli
SM10 [46] by transformation. The resulting recombinant E. coli
SM10 was then conjugated with BPZE1. Two successive
homologous recombination events were selected as described
[47]. The ex-conjugants were screened by PCR to ensure that the
hybrid gene was correctly inserted in the B. pertussis chromosome.
The recombinant BPZE1 strain was named BPZM2e. To
construct the FHA-deficient BPZM2e derivative BPZM2e-DFHA,
the FHA-encoding gene was inactivated using the integration
vector pFUS2, as previously described [24].
Table 1. B. pertussis strains used in this study.
Strain Description Reference
BPSM SmR and NalR derivative of B. pertussis
Tohama I
24
BPZE1 Attenuated vaccine strain derivative of
BPSM
5
BPGR4 FHA-deficient derivative of BPSM 50
BPZM2e BPZE1 derivative producing Fha44-(M2e)3 This work
BPZM2e-DFHA FHA-deficient BPZMe2 derivative This work
doi:10.1371/journal.pone.0059198.t001
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Protein Analysis and Immunodetection of Fha44-3M2e
For the detection of Fha44-3M2e, BPZM2e and BPZM2e-
DFHA, as well as BPZE1 were grown for 48 hours in 10 ml
Stainer-Scholte medium supplemented with 100 mg/ml Strepto-
mycin. The cells were then centrifuged for 15 minutes at 4,0006g.
Supernatant was collected, and the cells were resuspended in 1 ml
PBS. Cells were broken using a French Pressure cell, and the
lysates were clarified by centrifugation at 4,0006g for 15 min at
4uC. The culture supernatants and the whole cell extracts were
analyzed by SDS/polyacrylamide gel electrophoresis on 10%
polyacrylamide gels as described by Laemmli [48] and by
immunoblot analyses using an anti-M2e monoclonal antibody
[19] at a 1:3,000 dilution.
Mouse Infection
BALB/c mice were obtained from Charles River (l’Abresle,
France) and maintained under specific pathogen-free conditions in
the animal facilities of the Institut Pasteur de Lille. For B. pertussis
infection, 6 week-old BALB/c mice were lightly sedated by
intraperitoneal injection with an anesthetic cocktail (ketamine+a-
tropine+valium) before i.n. infection with 20 ml PBS containing
106 or 107 colony-forming units (CFU) of B. pertussis BPZE1,
BPZM2e, BPZM2e-DFHA or BPSM, as previously described [5].
The mice were sacrificed at selected time points after i.n.
administration, and their lungs were harvested, homogenized in
PBS and plated in serial dilutions onto BG-blood agar to count
CFUs after incubation at 37uC for three to four days, as described
[5,8]. When indicated, the mice were boosted i.n. 4 weeks after
priming with 10 mg M2e-VLP without adjuvant [36].
Antibody Detection
96-well plates were coated overnight at 4uC with 2 mg/ml of the
synthetic peptide M2e with the following sequence: GGSLLTE-
VETPIRNEWGSRSNDSSDGG, washed with PBS containing
0.05% Tween-20 (PBST) and then blocked with 100 ml/well of
blocking buffer (2% BSA in PBST) for 1 h at 37uC. After three
washes, 100 ml of serially diluted sera was added to the wells and
incubated for 2 h at 37uC. After another set of three washes, the
plates were incubated for 1 h at 37uC with 100 ml of horseradish-
peroxidase-labeled goat anti-mouse IgG, IgG1 or IgG2a (Southern
Biotech) diluted respectively at 1:4,000, 1:1,000 or 1:2,000 in
PBST. Following five washes, the plates were incubated with
100 ml of HRP Substrate TMB solution (Interchim) for 30 min at
room temperature. The reaction was stopped by the addition of
50 ml of 1 M H3PO4. The optical density (OD) was measured with
a Biokinetic reader EL/340 microplate at 450 nm. Titers were
determined as the highest serum dilution that had an optical
density reading more than twice that of the negative control
serum.
Viral Challenge
Two weeks after the last immunization the mice were
challenged. Fifty microliters of a lethal dose (4 LD50, correspond-
ing to 2.5 6 103 TCID50) of a mouse-adapted X47 virus (A/
Victoria/3/75 (H3N2)6PR/8) [19] was administered i.n. to mice
lightly anesthetized by isoflurane. Mortality was monitored on a
daily basis for 2 weeks. Morbidity was assessed by body weight
measurement.
Four days after challenge, 3 or 5 mice from each group were
sacrificed by cervical dislocation. Lungs were removed aseptically
and snap-frozen in liquid nitrogen. Lung extracts were made by
homogenizing the frozen tissue in a precooled mortar and
resuspending the homogenate in 5 ml of sterile, ice-cold PBS.
The extracts were transferred to centrifuge tubes, and cell debris
was removed by centrifugation for 5 min at 4006g and 4uC. The
cleared lung extracts were stored at 280uC. Viral titers were
determined in triplicate by titration on MDCK cells. Cell
monolayers were infected for 1 h with 50 ml of serial 1:10 dilutions
of the lung extracts in a 96-well plate in serum-free DMEM
medium (Invitrogen, Merelbeke, Belgium) supplemented with
penicillin and streptomycin. Following inoculation, the superna-
tant was replaced by serum-free DMEM medium containing
2 mg/ml trypsin. Endpoint virus titers were determined after 4
days, as described [49], by interpolating the dilution that infected
50% of the wells, as assayed by hemagglutination of chicken red
blood cells.
Statistical Analyses
The results were analyzed using the unpaired Student’s t-test
(GraphPad Prism Program). Differences were considered signifi-
cant at p,0.05.
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